CYP23 Antibody

Definition and Target Specificity

CYP3A23 is a hepatic enzyme encoded by the CYP3A23 gene in rats. Its human orthologs include CYP3A4 and CYP3A5, which share overlapping substrate specificities. The CYP23 antibody recognizes epitopes specific to CYP3A23, enabling its detection in immunoblotting, immunohistochemistry, and metabolic activity assays .

Role in Drug Metabolism

• Acetaminophen (APAP)-Induced Accumulation:

  • CYP3A23 protein levels and metabolic activity increased 1.5- to 2.5-fold in rat hepatocytes exposed to APAP (1–10 mM). This accumulation occurs via inhibition of protein degradation rather than transcriptional upregulation .

  • Mechanism: APAP stabilizes CYP3A23 by blocking ubiquitin-proteasome degradation pathways (Fig. 4 in ).

Antibody Validation and Cross-Reactivity

• Anti-CYP3A1 antibodies (cross-reactive with CYP3A23) were validated using:

  • Immunoblotting: Demonstrated specificity for CYP3A isoforms in dexamethasone-induced rat hepatocytes .

  • Activity Probes: Confirmed functional CYP3A activity via luciferin-IPA metabolic assays .

Comparative Analysis of CYP Antibodies

Clinical and Toxicological Implications

• Drug-Drug Interactions:

  • CYP3A23 inhibition or induction alters the metabolism of substrates like docetaxel and cyclophosphamide .

  • In psoriasis patients, IL-23 inhibitors (e.g., tildrakizumab) showed no significant impact on CYP3A4/5 activity, suggesting minimal risk of CYP-mediated drug interactions .

• Autoantibodies in Disease:

  • Anti-CYP2E1 IgG autoantibodies are elevated in trichloroethylene-hypersensitive patients, linking environmental exposures to autoimmune responses .

Technical Considerations

• Antibody Production:

  • Polyclonal antibodies against CYP isoforms are generated using synthetic peptides or recombinant proteins, ensuring subfamily specificity (e.g., CYP2C8/9/19 cross-reactivity) .

  • Monoclonal antibodies (MAbs) exhibit lower inhibitory capacity compared to polyclonal antibodies (PAbs) in immunoinhibition assays .

Future Directions

• Precision Medicine: Profiling CYP3A23 expression could optimize dosing regimens for CYP3A-metabolized drugs.

• Environmental Toxicology: Investigating CYP23’s role in metabolizing pollutants like polycyclic aromatic hydrocarbons (PAHs) may clarify toxicity mechanisms .